An interventional study of Jaspr and Jaspr-at-Home (JAH) in Suicide, sponsored by Evidence-Based Practice Institute, Seattle, WA. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Evidence-Based Practice Institute, Seattle, WA · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase II study is a continuation of the Phase I feasibility study where the investigators fully met and exceeded project aims to design, build, and test the usability and acceptability of an avatar-based system, Jaspr Health ("Jaspr"), for use by suicidal ED patients and medical personnel responsible for their care. Phase II includes a formative phase, during which the investigators will continue conducting usability and acceptability tests of new features, and a summative phase to conduct a clinical trial. SBIR Phase II project aims include: (1) Complete development of Jaspr, including readiness for electronic health record integration; (2) Cultivate and utilize the advisory board so that Jaspr is positioned to meet the needs of diverse healthcare systems and successful conduct of the proposed research; (3) Conduct usability/acceptability tests of new features with target end-users (suicidal patients, including those in the ED, medical providers) and key stakeholders (i.e., administrators); and (4) Conduct a randomized controlled trial (RCT; n=31) of suicidal ED patients comparing Jaspr (n=14) to Care-As-Usual (CAU; n=17). Participants were assessed at baseline while in the ED, and again at 7, 30, and 90 days. The investigators predicted that Jaspr participants will report a significantly greater decrease in suicidal behaviors and ED/hospital admissions, as well as significantly greater increases in use of behavioral coping skills, self-efficacy in coping with distress, and perceived helpfulness of patients' ED experience and satisfaction with the app. This study, however, was paused due to COVID after February, 2020 with a total of 31 participants recruited. The study later resumed at one site; however, because of COVID there were fewer admissions for suicidal behavior to the ED, only 7 participants were enrolled before the study ended recruitment in December, 2020 (RCT; n=7) (Jaspr; n=4) (CAU; n=3). The Telehealth clinical trial was conducted with suicidal outpatients to compare the Jaspr-At-Home companion mobile app (JAH; n=28) and CAU (in addition to crisis safety planning; n=26). Participants were assessed at baseline, 30- and 90-days after the initial session.
609 studies on the registry are indexed under Suicide; 163 are open to participants now.
This study's enrollment of 103 is close to the median of 104 across 492 interventional studies indexed under Suicide.
Browse Suicide studies →Evidence-Based Practice Institute, Seattle, WA is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Compared within Suicide, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ED RCT Inclusion Criteria:
"Suicidal Patient" is defined as those patients who:
"Clinically Stable" and not in clear and imminent danger is defined as:
The Site Contact or Coordinators and/or designated medical staff will determine if suicidal patients fit these criteria before referring them to the research team.
Telehealth RCT Inclusion Criteria:
Exclusion Criteria applicable to all:
Additional Exclusion Criteria for Telehealth RCT only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ED RCT: Phase I (formative): Participants are asked to provide feedback on the Jaspr prototype as it is being refined. Feedback will be gathered via survey measure and interview. Phase II (summative): Patient participants will be randomly assigned to this arm and will be given access to the Jaspr tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge will occur at 7 days, 30 days, and 90 days. Intent to treat sample is defined as completing post-treatment baseline assessment. Telehealth RCT: Outpatient participants will be randomly assigned to receive the Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups. Intent to treat threshold is defined as completing setup of JAH on their personal mobile phone.
Device: Jaspr · Device: Jaspr-at-Home (JAH)
ED RCT: Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Intent to treat sample is defined as completing post-treatment baseline assessment. Telehealth RCT: Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups. Intent to treat threshold is defined as setting up the control condition crisis stability plan.
Jaspr is an integrated software system for use on any device by suicidal patients.
Jaspr-at-Home is the mobile companion app to Jaspr.
Change in Suicide Cognitions Scale (SCS)
An 18-item psychometrically sound self-report measure, the Suicide Cognitions Scale (SCS) assesses suicidal schemas. Items are scored on a 5-point Likert scale (1=strongly disagree; 5=strongly agree). The score is found by summing the items for a total ranging from 18 to 90 with higher scores indicating worse outcomes. The scale is administered to patient participants at three time-points during the Telehealth RCT to assess change over time.
Time frame: Baseline, 30 days, and 90 days.
Change in Suicide Related Coping Scale (SRCS)
17-item, with 5 items scored in reverse, psychometrically-sound self-report measure of coping with suicidal thoughts, urges, and crises that uses a 5-point rating scale (0=strongly disagree; 4=strongly agree); the items are summed, so total range of the scale is 0 to 68, with higher scores indicating higher suicide related coping. It is administered to patient participants at three time-points during Telehealth RCT.
Time frame: Baseline, 30 days, and 90 days.
Emergency Room Patient Satisfaction Survey
A seven-item measure frequently used in clinical trials, modified for this study to focus on patient participants' emergency department. The Emergency Room Patient Satisfaction Survey is scored by summing the individual items to produce a range of 1 to 5, with higher scores indicating greater satisfaction. It is administered to patient participants at baseline during Phase II (summative) of the ED RCT.
Time frame: Baseline.
Change in Safety & Imminent Distress Scale (SIDQ)
A four-item self-report scale modified for this study to measure emotional distress and self-efficacy in coping with suicidality. For agitation, scores are 1=very calm to 10=very frustrated/agitated. For ability to cope, scores are 1=no ability to cope with thoughts of killing myself to 10=strong ability to cope with thoughts of killing myself. For distress, scores are 1=no distress to 10= the highest distress you have ever felt. Each item is averaged with lower values representing better outcomes for agitation and distress, and higher values representing better outcomes for ability to cope. It is administered to patient participants at each assessment point during Phase II (summative) ED RCT.
Time frame: Baseline, 7 days, 30 days, and 90 days.
Change in Depression Anxiety and Stress Scale (DASS-21)
A 21-item self-report measure frequently used in clinical trials, used to measure emotional states of depression, anxiety, and stress. The DASS-21 contains three subscales, depression, anxiety, and stress with seven items each. Each item was rated on a four point scale from 1 (Did not apply to me at all) to 4 (Applied to me very much or most of the time). Subscale totals are obtained by summing the seven item scores and multiplying by two to produce a range of 14 to 56 for each. Higher scores indicate higher severities of depression, anxiety, and stress. It is administered to patient participants at three time-points during the Phase II (summative) Telehealth RCT.
Time frame: Baseline, 30 days, and 90 days.
Change in Suicide-Related Coping Scale (SRCS)
This 17-item self-report measure, with 5-items reverse scored, is designed to assess a participant's capacity to cope effectively with their suicidal thoughts. Each item is rated on five point Likert scale from 0 (Strongly Disagree) to 4 (Strongly Agree). These items are summed, resulting in a scale range from 0 to 68, where higher scores indicate higher suicide related coping. It is administered to patient participants at each assessment time-points during Phase II (summative) ED RCT.
Time frame: Baseline, 7 days, 30 days, and 90 days.
Outpatient Satisfaction Questionnaire
An eight-item self-report measure to assess patient satisfaction with the care they received, perception of provider, and readiness to maintain safety. Items are rated on a scale of 1 (poor) to 5 (excellent), with higher scores indicating higher levels of satisfaction. It is administered to patient participants at baseline during Phase II (summative) Telehealth RCT.
Time frame: Baseline
Jaspr-At-Home Patient Satisfaction Survey
A 12-item self-report measure assessing the usability and satisfaction of the JAH mobile app. Items are averaged, resulting a scale range from 1 (Poor) to 5 (Excellent); higher scores indicate higher satisfaction and usability. It is administered to patient participants at two time-points during Phase II (summative) Telehealth RCT.
Time frame: 30 days and 90 days.
Jaspr Health Patient Satisfaction Survey
An 8-item self-report measure assessing the usability and satisfaction of the Jaspr app. Items are averaged, resulting in a scale range from 1(Poor) to 5 (Excellent). Higher scores indicate higher ease of use, helpfulness of the app, feeling cared about by the app, and helpfulness of information provided in the app. It is administered to patient participants at baseline during Phase II (summative) ED RCT.
Time frame: Baseline.
Change in Nock Intensity Rating Scale
This 6-item self-report measure is designed to assess a participant's intensity levels related to suicidal thoughts and ability to cope. Each item serves as its own subscale, and are individually scored and rated on a ten point Likert scale from 1 (Not at all) to 10 (Very Strong). For the desire and intention subscales, higher scores indicate worse outcomes. For the resist, safe, cope, and hope subscales, higher scores indicate better outcomes. It is administered to patient participants at each assessment time-points during Phase II (summative) ED and Telehealth RCT.
Time frame: Baseline, 7 days, 30 days, and 90 days.
Change in Optimism & Hope Scale
A 14-item self-report measure to assess optimism and hope. Items are scored on a 4-point Likert scale (1=definitely true; 4=definitely false). A total score, 14-56, is obtained by summing scores for each item. The mean score (minimum= 1; maximum= 4) is then calculated by dividing the total score by the number of items in the measure. Lower scores indicate increased optimism and hope. It is administered to patient participants at each assessment time-point during the Telehealth RCT and ED RCT.
Time frame: Baseline, 7 days, 30 days, and 90 days.
Emergency Department (ED) RCT: We recruited acutely suicidal individuals seeking ED-based psychiatric crisis services from 2 EDs. Patients were randomized to Jaspr or Care-as-usual (CAU). Providers in the EDs referred patients to the study. Telehealth RCT: We recruited outpatients from 3 behavioral health clinics. Outpatients were randomized to Jaspr-at-Home (JAH) or CAU. Providers referred existing patients to the study. Those eligible and consented were assigned to a random condition.
| Milestone | Jaspr | Care As Usual |
|---|---|---|
| Started | 20 | 20 |
| Completed | 10 | 18 |
| Not completed | 10 | 2 |
| Withdrew: Lost to follow-up | 9 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Jaspr | Care As Usual |
|---|---|---|
| Started | 32 | 31 |
| Completed | 23 | 21 |
| Not completed | 9 | 10 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Withdrawal by subject | 4 | 5 |
An 18-item psychometrically sound self-report measure, the Suicide Cognitions Scale (SCS) assesses suicidal schemas. Items are scored on a 5-point Likert scale (1=strongly disagree; 5=strongly agree). The score is found by summing the items for a total ranging from 18 to 90 with higher scores indicating worse outcomes. The scale is administered to patient participants at three time-points during the Telehealth RCT to assess change over time.
| units on a scale | Jaspr-at-Home | Care As Usual |
|---|---|---|
| T0 | 51.84 ± 13.81 | 47.57 ± 16.27 |
| T30 | 50.61 ± 14.39 | 45.76 ± 17.35 |
| T90 | 42.91 ± 13.62 | 40.86 ± 15.36 |
17-item, with 5 items scored in reverse, psychometrically-sound self-report measure of coping with suicidal thoughts, urges, and crises that uses a 5-point rating scale (0=strongly disagree; 4=strongly agree); the items are summed, so total range of the scale is 0 to 68, with higher scores indicating higher suicide related coping. It is administered to patient participants at three time-points during Telehealth RCT.
| Scores on a scale | Jaspr-at-Home | Care As Usual |
|---|---|---|
| T0 | 42.48 ± 8.65 | 43.31 ± 11.74 |
| T30 | 46.85 ± 10.14 | 45.07 ± 12.56 |
| T90 | 48.79 ± 10.10 | 48.33 ± 11.58 |
A seven-item measure frequently used in clinical trials, modified for this study to focus on patient participants' emergency department. The Emergency Room Patient Satisfaction Survey is scored by summing the individual items to produce a range of 1 to 5, with higher scores indicating greater satisfaction. It is administered to patient participants at baseline during Phase II (summative) of the ED RCT.
| units on a scale | Jaspr | Care As Usual |
|---|---|---|
| Care from team | 3.93 ± 1.16 | 3.55 ± 1.23 |
| Felt listened to | 4.07 ± .884 | 3.50 ± 1.23 |
| Readiness to leave | 3.07 ± 1.48 | 2.60 ± 1.42 |
| Likelihood of recommendation | 4.27 ± 1.16 | 3.55 ± 1.23 |
| Visit helpfulness | 3.60 ± .828 | 3.05 ± 1.23 |
A four-item self-report scale modified for this study to measure emotional distress and self-efficacy in coping with suicidality. For agitation, scores are 1=very calm to 10=very frustrated/agitated. For ability to cope, scores are 1=no ability to cope with thoughts of killing myself to 10=strong ability to cope with thoughts of killing myself. For distress, scores are 1=no distress to 10= the highest distress you have ever felt. Each item is averaged with lower values representing better outcomes for agitation and distress, and higher values representing better outcomes for ability to cope. It is administered to patient participants at each assessment point during Phase II (summative) ED RCT.
| units on a scale | Jaspr (ED RCT) | Care As Usual |
|---|---|---|
| ED0 - Agitation | 5.67 ± 2.44 | 5.80 ± 2.67 |
| ED7 - Agitation | 3.08 ± 1.71 | 3.83 ± 2.36 |
| ED30 - Agitation | 4.00 ± 2.41 | 4.32 ± 2.96 |
| ED90 - Agitation | 3.22 ± 2.49 | 3.94 ± 2.01 |
| ED0 - Ability to Cope | 4.64 ± 2.21 | 5.00 ± 2.47 |
| ED7 - Ability to Cope | 7.69 ± 2.72 | 7.63 ± 2.17 |
| ED30 - Ability to Cope | 8.71 ± 2.53 | 8.26 ± 2.33 |
| ED90 - Ability to Cope | 8.11 ± 2.80 | 7.06 ± 2.82 |
| ED0 - Distress | 6.87 ± 2.13 | 6.85 ± 2.76 |
| ED7 - Distress | 3.38 ± 1.45 | 5.44 ± 2.68 |
| ED30 - Distress | 3.57 ± 2.03 | 4.11 ± 1.99 |
| ED90 - Distress | 3.13 ± 2.10 | 4.28 ± 2.74 |
A 21-item self-report measure frequently used in clinical trials, used to measure emotional states of depression, anxiety, and stress. The DASS-21 contains three subscales, depression, anxiety, and stress with seven items each. Each item was rated on a four point scale from 1 (Did not apply to me at all) to 4 (Applied to me very much or most of the time). Subscale totals are obtained by summing the seven item scores and multiplying by two to produce a range of 14 to 56 for each. Higher scores indicate higher severities of depression, anxiety, and stress. It is administered to patient participants at three time-points during the Phase II (summative) Telehealth RCT.
| units on a scale | Jaspr-at-Home | Care As Usual |
|---|---|---|
| T0 - Depression | 42.00 ± 9.10 | 39.59 ± 11.55 |
| T30 - Depression | 37.92 ± 11.28 | 34.56 ± 12.58 |
| T90 - Depression | 35.74 ± 9.50 | 33.70 ± 9.92 |
| T0 - Anxiety | 35.28 ± 9.79 | 29.87 ± 8.35 |
| T30 - Anxiety | 31.97 ± 9.10 | 30.32 ± 8.58 |
| T90 - Anxiety | 31.14 ± 8.57 | 28.08 ± 7.89 |
| T0 - Stress | 40.81 ± 9.42 | 36.27 ± 8.42 |
| T30 - Stress | 38.23 ± 9.30 | 34.27 ± 9.36 |
| T90 - Stress | 34.79 ± 7.56 | 33.22 ± 8.39 |
This 17-item self-report measure, with 5-items reverse scored, is designed to assess a participant's capacity to cope effectively with their suicidal thoughts. Each item is rated on five point Likert scale from 0 (Strongly Disagree) to 4 (Strongly Agree). These items are summed, resulting in a scale range from 0 to 68, where higher scores indicate higher suicide related coping. It is administered to patient participants at each assessment time-points during Phase II (summative) ED RCT.
| Scores on a scale | Jaspr | Care As Usual |
|---|---|---|
| ED0 | 34.6 ± 5.6 | 37.26 ± 12.39 |
| ED7 | 49.77 ± 6.57 | 50.00 ± 10.01 |
| ED30 | 48.48 ± 10.50 | 53.73 ± 9.58 |
| ED90 | 49.66 ± 13.23 | 50.29 ± 10.30 |
An eight-item self-report measure to assess patient satisfaction with the care they received, perception of provider, and readiness to maintain safety. Items are rated on a scale of 1 (poor) to 5 (excellent), with higher scores indicating higher levels of satisfaction. It is administered to patient participants at baseline during Phase II (summative) Telehealth RCT.
| units on a scale | Jaspr-at-Home | Care As Usual |
|---|---|---|
| Helpfulness | 3.68 ± .820 | 4.03 ± .808 |
| Feel listened to | 4.0 ± .984 | 4.20 ± .847 |
| Care | 3.88 ± 1.13 | 4.27 ± .78 |
| Readiness to keep home safe | 3.44 ± 1.01 | 3.90 ± 1.09 |
| Recommend | 4.16 ± 1.02 | 4.33 ± .922 |
| Overall care | 4.13 ± .906 | 4.23 ± .817 |
A 12-item self-report measure assessing the usability and satisfaction of the JAH mobile app. Items are averaged, resulting a scale range from 1 (Poor) to 5 (Excellent); higher scores indicate higher satisfaction and usability. It is administered to patient participants at two time-points during Phase II (summative) Telehealth RCT.
| units on a scale | Jaspr-at-Home |
|---|---|
| Ease | 3.95 ± .963 |
| JAH Helpfulness | 3.34 ± 1.20 |
| Care | 3.50 ± 1.21 |
| DSG Helpfulness | 3.30 ± 1.15 |
| Recommend | 3.77 ± 1.16 |
An 8-item self-report measure assessing the usability and satisfaction of the Jaspr app. Items are averaged, resulting in a scale range from 1(Poor) to 5 (Excellent). Higher scores indicate higher ease of use, helpfulness of the app, feeling cared about by the app, and helpfulness of information provided in the app. It is administered to patient participants at baseline during Phase II (summative) ED RCT.
| units on a scale | Jaspr |
|---|---|
| Ease | 4.47 ± .743 |
| Helpfulness | 4.00 ± .756 |
| Care | 3.93 ± .961 |
| Info | 4.13 ± .834 |
This 6-item self-report measure is designed to assess a participant's intensity levels related to suicidal thoughts and ability to cope. Each item serves as its own subscale, and are individually scored and rated on a ten point Likert scale from 1 (Not at all) to 10 (Very Strong). For the desire and intention subscales, higher scores indicate worse outcomes. For the resist, safe, cope, and hope subscales, higher scores indicate better outcomes. It is administered to patient participants at each assessment time-points during Phase II (summative) ED and Telehealth RCT.
| units on a scale | Jaspr/Jaspr-at-Home | Care As Usual |
|---|---|---|
| T0 - Desire | 2.72 ± 1.65 | 2.46 ± 1.64 |
| T30 - Desire | 2.81 ± 2.12 | 2.43 ± 1.73 |
| T90 - Desire | 2.43 ± 1.91 | 2.35 ± 1.81 |
| T0 - Intention | 1.56 ± 1.09 | 1.36 ± .810 |
| T30 - Intention | 1.68 ± 1.25 | 1.59 ± 1.01 |
| T90 - Intention | 1.41 ± .87 | 1.26 ± .452 |
| T0 - Resist | 8.75 ± 1.43 | 8.27 ± 2.73 |
| T30 - Resist | 8.96 ± 1.37 | 8.21 ± 2.536 |
| T90 - Resist | 9.13 ± 1.29 | 8.81 ± 1.78 |
| T0 - Safe | 7.71 ± 3.16 | 7.76 ± 3.09 |
| T30 - Safe | 7.96 ± 2.85 | 8.00 ± 2.94 |
| T90 - Safe | 8.39 ± 2.52 | 8.57 ± 1.96 |
| T0 - Cope | 8.23 ± 1.99 | 7.93 ± 2.18 |
| T30 - Cope | 7.96 ± 2.20 | 7.96 ± 2.41 |
| T90 - Cope | 8.74 ± 1.98 | 8.86 ± 1.49 |
| T0 - Hope | 5.03 ± 2.10 | 5.44 ± 2.44 |
| T30 - Hope | 5.19 ± 2.35 | 5.20 ± 3.10 |
| T90 - Hope | 6.04 ± 2.33 | 5.95 ± 2.65 |
| ED0 - Desire | 5.20 ± 2.51 | 5.00 ± 2.85 |
| ED7 - Desire | 2.44 ± 1.13 | 3.00 ± 2.90 |
| ED30 - Desire | 2.17 ± 1.33 | 2.07 ± 1.27 |
| ED90 - Desire | 1.57 ± .976 | 2.56 ± 2.16 |
| ED0 - Intention | 3.58 ± 2.28 | 4.17 ± 3.10 |
| ED7 - Intention | 1.50 ± .756 | 1.86 ± 1.41 |
| ED30 - Intention | 1.38 ± .744 | 1.43 ± .852 |
| ED90 - Intention | 1.43 ± 1.13 | 2.0 ± 1.56 |
| ED0 - Resist | 7.29 ± 2.128 | 6.63 ± 3.22 |
| ED7 - Resist | 8.92 ± 1.85 | 7.63 ± 3.10 |
| ED30 - Resist | 8.79 ± 2.36 | 8.47 ± 2.95 |
| ED90 - Resist | 7.67 ± 3.12 | 8.35 ± 2.42 |
| ED0 - Safe | 7.29 ± 2.89 | 7.21 ± 3.38 |
| ED7 - Safe | 9.38 ± 1.19 | 7.95 ± 2.48 |
| ED30 - Safe | 8.64 ± 2.53 | 8.74 ± 2.20 |
| ED90 - Safe | 9.67 ± .707 | 8.06 ± 2.60 |
| ED0 - Cope | 6.17 ± 2.21 | 6.70 ± 2.86 |
| ED7 - Cope | 8.92 ± 1.75 | 8.89 ± 1.60 |
| ED30 - Cope | 8.57 ± 2.14 | 8.26 ± 2.77 |
| ED90 - Cope | 8.38 ± 2.45 | 7.94 ± 1.98 |
| ED0 - Hope | 4.42 ± 2.68 | 3.53 ± 1.66 |
| ED7 - Hope | 7.15 ± 1.68 | 6.53 ± 2.67 |
| ED30 - Hope | 7.50 ± 2.47 | 7.47 ± 2.31 |
| ED90 - Hope | 7.22 ± 2.11 | 6.33 ± 3.0 |
A 14-item self-report measure to assess optimism and hope. Items are scored on a 4-point Likert scale (1=definitely true; 4=definitely false). A total score, 14-56, is obtained by summing scores for each item. The mean score (minimum= 1; maximum= 4) is then calculated by dividing the total score by the number of items in the measure. Lower scores indicate increased optimism and hope. It is administered to patient participants at each assessment time-point during the Telehealth RCT and ED RCT.
| units on a scale | Jaspr (ED RCT) / JAH (Telehealth RCT) | Care As Usual |
|---|---|---|
| T0 | 2.55 ± .41 | 2.50 ± .33 |
| T30 | 2.55 ± .39 | 2.38 ± .38 |
| T90 | 2.45 ± .38 | 2.26 ± .35 |
| ED0 | 2.84 ± .54 | 2.90 ± .47 |
| ED7 | 2.41 ± .29 | 2.45 ± .49 |
| ED30 | 2.35 ± .54 | 2.36 ± .50 |
| ED90 | 2.30 ± .67 | 2.45 ± .54 |
Collected over Adverse event data was collected over the duration of the study (90 days each for the ED RCT and the Telehealth RCT). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Jaspr | 0/52 (0%) | 0/52 (0%) | 17/52 (32.7%) |
| Care As Usual | 0/50 (0%) | 0/50 (0%) | 17/50 (34%) |
| Event | Jaspr | Care As Usual |
|---|---|---|
| Unauthorized Disclosure of Participant Names to Other ParticipantsSocial circumstances | 16/52 | 15/50 |
| Crisis Hotline OfferedPsychiatric disorders | 1/52 | 3/50 |
The periods listed in the Participant Flow reflect the total numbers started, completed, and not completed for each RCT, the ED RCT and the Telehealth RCT. The overall number of baseline participants combines the ED RCT and Telehealth RCT totals and differs from the enrollment number because of missing data and 1 participant was lost to follow-up before baseline data was collected
| Age, Categorical(Participants) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| ED RCT — <=18 years | 0 | 1 | 1 |
| ED RCT — Between 18 and 65 years | 11 | 14 | 25 |
| ED RCT — >=65 years | 0 | 2 | 2 |
| Age, Continuous(years) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| ED RCT | 26.73 ± 10.297 | 39.06 ± 16.92 | 34.21 ± 15.70 |
| Sex: Female, Male(Participants) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| ED RCT — Female | 6 | 11 | 17 |
| ED RCT — Male | 5 | 6 | 11 |
| Telehealth RCT — Female | 27 | 27 | 54 |
| Telehealth RCT — Male | 5 | 4 | 9 |
| Race (NIH/OMB)(Participants) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| ED RCT — American Indian or Alaska Native | 0 | 0 | 0 |
| ED RCT — Asian | 0 | 0 | 0 |
| ED RCT — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| ED RCT — Black or African American | 0 | 1 | 1 |
| ED RCT — White | 9 | 15 | 24 |
| ED RCT — More than one race | 2 | 1 | 3 |
| ED RCT — Unknown or Not Reported | 0 | 0 | 0 |
| Telehealth RCT — American Indian or Alaska Native | 0 | 0 | 0 |
| Telehealth RCT — Asian | 0 | 2 | 2 |
| Telehealth RCT — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Telehealth RCT — Black or African American | 0 | 0 | 0 |
| Telehealth RCT — White | 29 | 25 | 54 |
| Telehealth RCT — More than one race | 3 | 4 | 7 |
| Telehealth RCT — Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| ED RCT — Hispanic or Latino | 1 | 0 | 1 |
| ED RCT — Not Hispanic or Latino | 10 | 17 | 27 |
| ED RCT — Unknown or Not Reported | 0 | 0 | 0 |
| Telehealth RCT — Hispanic or Latino | 3 | 3 | 6 |
| Telehealth RCT — Not Hispanic or Latino | 29 | 28 | 57 |
| Telehealth RCT — Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Count of Participants) | Jaspr | Care As Usual | Total |
|---|---|---|---|
| United States | 43 | 48 | 91 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for use of data will be considered on a case-by-case basis. Interested researchers may send data requests to research@ebpi.org
Ran from Oct 2018 to primary completion in Mar 2021, 29 months.
Results were first posted in Oct 2026, 5 years 6 months after primary completion.
Of 321 interventional studies with no phase under Suicide, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evidence-Based Practice Institute, Seattle, WA